Duke startup focused on treating depression falls short of fundraising goal


A Duke startup working to develop a treatment for depression has brought in close to $2 million, but has fallen well short of its target.

Previous Her biotech company is blasting industry standards for ear self-care
Next Case dismissed in Atrium Health dispute over employee benefits